Fairmont Banff Springs Floorplan
This meeting took place in 2023
Here are the related meetings in 2024:
Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance (C2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Cancer Immunotherapy: Mechanisms of Response versus Resistance (C2)
Organizer(s) Thomas Gajewski, Nina Bhardwaj and Stanley R. Riddell
March 5—9, 2023
Fairmont Banff Springs • Banff, AB Canada
Abstract Deadline: Dec 6, 2022
Scholarship Deadline: Dec 6, 2022
Discounted Registration Deadline: Jan 10, 2023
Sponsored by (Cell Research), Chinese Society for Cell Biology, Genmab A/S, GlaxoSmithKline Biologicals, Janssen R&D: Pharmaceutical Companies of Johnson & Johnson and Surface Oncology
Summary of Meeting:
The notion that the immune system is capable of recognizing and destroying cancer has become a clinical reality with the development, approval, and implementation of novel immunotherapies. Blockade of immune inhibitory receptors, adoptive T cell therapy, vaccination against tumor antigens, and engagement of innate immune pathways have all reached the standard-of-care arena. However, as many patients fail to respond to these therapies, there is much work to be done to bridge the gap and expand the circle of efficacy. Fundamental immunology research is identifying additional molecular and cellular features of regulation of endogenous anti-tumor immune responses. New approaches to T cell engineering are being investigated, and engineering of other immune cells is being pursued. Bioinformatic approaches to streamline neoantigen identification are being utilized, and novel vaccine platforms are being tested. Since a major determinant of efficacy is driven by the biology of the tumor microenvironment, single cell technologies and in situ tissue imaging are being carried out. Interrogation of patient samples is providing a key resource for understanding treatment failure, and molecular details of the tumor, genetics of the host, and the composition of the gut microbiome are features defined already that impact on immunotherapy outcomes. Analysis of each of these dimensions is pointing towards new therapeutic interventions.
View Scholarships/Awards
The notion that the immune system is capable of recognizing and destroying cancer has become a clinical reality with the development, approval, and implementation of novel immunotherapies. Blockade of immune inhibitory receptors, adoptive T cell therapy, vaccination against tumor antigens, and engagement of innate immune pathways have all reached the standard-of-care arena. However, as many patients fail to respond to these therapies, there is much work to be done to bridge the gap and expand the circle of efficacy. Fundamental immunology research is identifying additional molecular and cellular features of regulation of endogenous anti-tumor immune responses. New approaches to T cell engineering are being investigated, and engineering of other immune cells is being pursued. Bioinformatic approaches to streamline neoantigen identification are being utilized, and novel vaccine platforms are being tested. Since a major determinant of efficacy is driven by the biology of the tumor microenvironment, single cell technologies and in situ tissue imaging are being carried out. Interrogation of patient samples is providing a key resource for understanding treatment failure, and molecular details of the tumor, genetics of the host, and the composition of the gut microbiome are features defined already that impact on immunotherapy outcomes. Analysis of each of these dimensions is pointing towards new therapeutic interventions.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, March 5 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 9 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Friday, March 10 in order to fully experience the meeting.
SUNDAY, MARCH 5
MONDAY, MARCH 6
TUESDAY, MARCH 7
WEDNESDAY, MARCH 8
THURSDAY, MARCH 9
FRIDAY, MARCH 10
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 5 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 9 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Friday, March 10 in order to fully experience the meeting.
SUNDAY, MARCH 5
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address (8am Start)
*
Thomas Gajewski,
University of Chicago, USA
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade: Where do we go from Here?
Checkpoint Blockade: Where do we go from Here?
09:00—11:15
Dysfunctional Immune Cells in the TME (9am Start)
*
Patrick G. Hogan,
La Jolla Institute for Immunology, USA
Transcriptional Mechanisms of CD8 TIL Dysfunction
Transcriptional Mechanisms of CD8 TIL Dysfunction
Coffee Break
*
Michael Karin,
University of California, San Diego, USA
Inflammation and Cancer: A Double Edged Sword
Inflammation and Cancer: A Double Edged Sword
Evan W. Newell,
Fred Hutchinson Cancer Research Center, USA
Understanding TIL Dysfunction using scRNAseq
Understanding TIL Dysfunction using scRNAseq
Maria Angela Aznar Gomez,
University of Pennsylvania, USA
Short Talk: Improving CAR T Therapy by Targeting Transcription Factors driving CAR T Cell Dysfunction
Short Talk: Improving CAR T Therapy by Targeting Transcription Factors driving CAR T Cell Dysfunction
14:30—16:30
Workshop 1 (2:30pm Start)
*
Ronal M. Peralta,
University of Pittsburgh, USA
Lactic Acid Uptake through MCT11 Enforces Dysfunction in Terminally Exhausted T Cells
Lactic Acid Uptake through MCT11 Enforces Dysfunction in Terminally Exhausted T Cells
*
Ines Delclaux,
NYU Langone Health, USA
Defining the Fate of Egressing Tumor-specific T Cells and Role in Regional LN Metastasis
Defining the Fate of Egressing Tumor-specific T Cells and Role in Regional LN Metastasis
Michael Plebanek,
Duke University, USA
A SREBF2 Gene Program Drives an Immunotolerant Dendritic Cell Population During Cancer Progression
A SREBF2 Gene Program Drives an Immunotolerant Dendritic Cell Population During Cancer Progression
Thomas H. Mann,
The Salk Institute for Biological Studies, USA
Discovery of a Molecular Clock that Controls CD8+ T Cell Function and Exhaustion
Discovery of a Molecular Clock that Controls CD8+ T Cell Function and Exhaustion
Aya Ludin Tal,
Harvard University, USA
Craters on the Melanoma Surface Serve as Hubs for CD8+ T Cells
Craters on the Melanoma Surface Serve as Hubs for CD8+ T Cells
Jason M. Schenkel,
University of Texas MD Anderson Cancer Center, USA
Continual Systemic Treg Recruitment to Tumors Mediate Local Immunosuppression
Continual Systemic Treg Recruitment to Tumors Mediate Local Immunosuppression
Erietta Stelekati,
University of Miami, USA
microRNA-29a Promotes T Cell Responses to Anti-PD-1 Therapy
microRNA-29a Promotes T Cell Responses to Anti-PD-1 Therapy
17:00—19:00
Innate Immune Cells in the Cancer Context (5pm Start)
*
Marco Colonna,
Washington University School of Medicine, USA
TREM2 and Macrophages
TREM2 and Macrophages
*
Barbara Maier,
Center for Molecular Medicine of the Austrian Academy of Sciences, Austria
Innate Regulators of Tumor-directed T Cell Immunity
Innate Regulators of Tumor-directed T Cell Immunity
Stefani Spranger,
Massachusetts Institute of Technology, USA
Dendritic Cells in Anti-Tumor Immunity
Dendritic Cells in Anti-Tumor Immunity
Jemma Longley,
University of Southampton, UK
Short Talk: MicroRNA Manipulation of Macrophage Polarisation Status
Short Talk: MicroRNA Manipulation of Macrophage Polarisation Status
Pauline Hamon,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: TREM2-associated Signature Defines a Tumor-enriched Macrophage Subset Associated with Response to Checkpoint Blockade in Patients with Hepatocellular Carcinoma
Short Talk: TREM2-associated Signature Defines a Tumor-enriched Macrophage Subset Associated with Response to Checkpoint Blockade in Patients with Hepatocellular Carcinoma
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Vaccines (8am Start)
*
Nina Bhardwaj,
Icahn School of Medicine at Mount Sinai, USA
Properties of Tumor Neoantigens Determining Induction of Immunity
Properties of Tumor Neoantigens Determining Induction of Immunity
*
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Neoepitope Vaccines
Neoepitope Vaccines
Coffee Break
Robert D. Schreiber,
Washington University School of Medicine, USA
Integrating CD4 and CD8 Epitopes
Integrating CD4 and CD8 Epitopes
Jonathan Linehan,
Genentech, Inc., USA
Short Talk: Neoantigen Targeted Therapy Promotes Expansion of CD4+ T Follicular Helper Cells and Induces Rejection of Established Tumors in Mice
Short Talk: Neoantigen Targeted Therapy Promotes Expansion of CD4+ T Follicular Helper Cells and Induces Rejection of Established Tumors in Mice
Camille-Charlotte Balanca,
Genentech, Inc., USA
Short Talk: CD4 Neoantigen mRNA Vaccine Enhances Endogenous CD8 T Cell Responses and Tumor Control
Short Talk: CD4 Neoantigen mRNA Vaccine Enhances Endogenous CD8 T Cell Responses and Tumor Control
Robbert M. Spaapen,
Neogene Therapeutics, Netherlands
Short Talk: Development of a Personalized Neoantigen Specific TCR Discovery Platform
Short Talk: Development of a Personalized Neoantigen Specific TCR Discovery Platform
Summit Singhaviranon,
University of Connecticut Health Center, USA
Short Talk: High Avidity CD8 Tumor Infiltrating Lymphocytes are More Exhausted and Less Responsive to Immune Checkpoint Blockade than their Low Avidity Counterparts
Short Talk: High Avidity CD8 Tumor Infiltrating Lymphocytes are More Exhausted and Less Responsive to Immune Checkpoint Blockade than their Low Avidity Counterparts
14:30—16:30
Career Roundtable (2:30pm Start)
Padmanee Sharma,
University of Texas MD Anderson Cancer Center, USA
Carla V. Rothlin,
Yale University, USA
Andrew M. Scharenberg,
Umoja Biopharma, USA
Christine Carine Moussion,
Genentech, Inc., USA
17:00—19:00
Tumor Microenvironment (5pm Start)
*
Janis Taube,
Johns Hopkins University, USA
In situ Imaging of the Tumor Microenvironment
In situ Imaging of the Tumor Microenvironment
*
Ruan Vieira Medrano,
Washington University School of Medicine, USA
Short Talk: Successful Immune-Checkpoint Therapy Promotes Spatial Re-Organization of the Myeloid and Lymphoid Compartments
Short Talk: Successful Immune-Checkpoint Therapy Promotes Spatial Re-Organization of the Myeloid and Lymphoid Compartments
Kelly McKenna,
Fred Hutchinson Cancer Center, USA
Short Talk: Elucidating Mechanisms of T Cell Exclusion in Melanoma
Short Talk: Elucidating Mechanisms of T Cell Exclusion in Melanoma
Andrea Ziblat,
University of Chicago, USA
Short Talk: Batf3 Dendritic Cells and 4-1BB/4-1BB Ligand Axis are Required at the Effector Phase within the Tumor Microenvironment for PD-1/PD-L1 Blockade Efficacy
Short Talk: Batf3 Dendritic Cells and 4-1BB/4-1BB Ligand Axis are Required at the Effector Phase within the Tumor Microenvironment for PD-1/PD-L1 Blockade Efficacy
Sylvain Simon,
Fred Hutchinson Cancer Research Center, USA
Short Talk: Multispecific Hybrid T Cell Receptors for Sensitive Targeting of Multiple Myeloma
Short Talk: Multispecific Hybrid T Cell Receptors for Sensitive Targeting of Multiple Myeloma
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Host Factors Impacting Immunotherapy Efficacy (8am Start)
*
Thomas Gajewski,
University of Chicago, USA
Germline Variants Regulating Ani-Tumor Immunity
Germline Variants Regulating Ani-Tumor Immunity
*
Bertrand Routy,
Centre hospitalier de l’Université de Montréal, Canada
Gut Immune Checkpoint in Cancer Immunotherapy
Gut Immune Checkpoint in Cancer Immunotherapy
Coffee Break
Jennifer McQuade,
MDAnderson Cancer Center, USA
Modifiable Host Factors, the Microbiome and Anti-tumor Immunity
Modifiable Host Factors, the Microbiome and Anti-tumor Immunity
Michelle Krogsgaard,
NYU Langone Health, USA
Structure-activity Based Validation of Neoantigen Immunogenicity
Structure-activity Based Validation of Neoantigen Immunogenicity
Siva Karthik Varanasi,
The Salk Institute for Biological Studies, USA
Short Talk: Bile Acids Acts as a Metabolic Checkpoint within Liver Tumor that Imparts Resistance to Immunotherapy
Short Talk: Bile Acids Acts as a Metabolic Checkpoint within Liver Tumor that Imparts Resistance to Immunotherapy
Christine Carine Moussion,
Genentech, Inc., USA
Short Talk: Negative Impact of the GABA Pathway on αPD-1/PD-L1 Immunotherapy
Short Talk: Negative Impact of the GABA Pathway on αPD-1/PD-L1 Immunotherapy
14:30—16:30
Workshop 2 (2:30pm Start)
*
Taylor Heim,
New York University, USA
Resident Memory T Cells in the Lymph Node Balance Localized and Systemic Protection
Resident Memory T Cells in the Lymph Node Balance Localized and Systemic Protection
*
William Sam Nutt,
University of Washington and Fred Hutchinson Cancer Center, USA
Insufficient Activation of CAR-T Cells in Tumor-draining Lymph Nodes Correlates with their Poor Persistence Relative to TCR-T Cells in Solid Tumors
Insufficient Activation of CAR-T Cells in Tumor-draining Lymph Nodes Correlates with their Poor Persistence Relative to TCR-T Cells in Solid Tumors
Kristen Elaine Pauken,
University of Texas MD Anderson Cancer Center, USA
PD-1 Regulates Tumor-infiltrating CD8 T Cells in both a Cell-intrinsic and Cell-extrinsic Fashion
PD-1 Regulates Tumor-infiltrating CD8 T Cells in both a Cell-intrinsic and Cell-extrinsic Fashion
Junzhe Zhao,
National Cancer Centre Singapore, Singapore
Distinct Macrophage Characteristics in Viral and Non-alcoholic Fatty Liver Disease (NAFLD) Related Hepatocellular Carcinoma (HCC)
Distinct Macrophage Characteristics in Viral and Non-alcoholic Fatty Liver Disease (NAFLD) Related Hepatocellular Carcinoma (HCC)
Xiao Min Schebye,
Immune-Onc Therapeutics, Inc., USA
Anti-LAIR1 Antagonistic Antibodies Block Collagen-mediated Suppression of T Cell Activation
Anti-LAIR1 Antagonistic Antibodies Block Collagen-mediated Suppression of T Cell Activation
Takehito Uruno,
Kyushu University, Japan
A Tumor Metabolite Impacting Immunotherapy Efficacy: Cholesterol Sulfate Regulates Tumor-immune Interactions
A Tumor Metabolite Impacting Immunotherapy Efficacy: Cholesterol Sulfate Regulates Tumor-immune Interactions
Stephen Mok,
MD Anderson Cancer Center, USA
Late CTLA-4 Ig Treatment Improves Antitumor Efficacy of Immunotherapy
Late CTLA-4 Ig Treatment Improves Antitumor Efficacy of Immunotherapy
17:00—19:00
Innate Immune Pathways and the Anti-Tumor Response (5pm Start)
*
Carla V. Rothlin,
Yale University, USA
MerTK Family in Anti-Tumor Immunity
MerTK Family in Anti-Tumor Immunity
*
Chengcheng Alec Zhang,
University of Texas Southwestern Medical Center, USA
LILRBs - Myeloid Checkpoint Targets for Cancer Treatment
LILRBs - Myeloid Checkpoint Targets for Cancer Treatment
Brian Ruffell,
H. Lee Moffitt Cancer Center & Research Institute, USA
TIM-3 and the STING Pathway in Dendritic Cells
TIM-3 and the STING Pathway in Dendritic Cells
Ashley Reid Cahn,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Harnessing Epigenetic Therapies for Cancer Vaccine Efficacy
Short Talk: Harnessing Epigenetic Therapies for Cancer Vaccine Efficacy
Rachael Marie Zemek,
Telethon Kids Institute, Australia
Short Talk: Responders vs Non-responders: Temporal Transcriptomics during Immune Checkpoint Therapy Reveals Dynamic Activation of IFNβ Determines Response.
Short Talk: Responders vs Non-responders: Temporal Transcriptomics during Immune Checkpoint Therapy Reveals Dynamic Activation of IFNβ Determines Response.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Learning from the Patient: Reverse Translation (8am Start)
*
Padmanee Sharma,
University of Texas MD Anderson Cancer Center, USA
From the Clinic to The Lab: Investigating Myeloid Cells and Epigenetic Pathways that Drive Resistance to Immune Checkpoint Therapy
From the Clinic to The Lab: Investigating Myeloid Cells and Epigenetic Pathways that Drive Resistance to Immune Checkpoint Therapy
Christian U. Blank,
Netherlands Cancer Institute - NKI-AVL, Netherlands
Biomarkers of Response to Neoadjuvant Checkpoint Blockade
Biomarkers of Response to Neoadjuvant Checkpoint Blockade
Coffee Break
David R. Glass,
Fred Hutchinson Cancer Center, USA
Integration of Multi-omic Data into Immune Modules Predictive of Response to Checkpoint Blockade in Cutaneous T Cell Lymphoma
Integration of Multi-omic Data into Immune Modules Predictive of Response to Checkpoint Blockade in Cutaneous T Cell Lymphoma
Assaf Magen,
Icahn School of Medicine at Mount Sinai, USA
Intratumoral DC/T Helper Niches Enable Local Reactivation of CD8 T Cells upon PD-1 Blockade
Intratumoral DC/T Helper Niches Enable Local Reactivation of CD8 T Cells upon PD-1 Blockade
Kelsey B. Bennion,
Emory University, USA
Short Talk: FcγRIIB Expressed on CD8 T Cells Limits Responsiveness to PD-1 Checkpoint Inhibition in Cancer
Short Talk: FcγRIIB Expressed on CD8 T Cells Limits Responsiveness to PD-1 Checkpoint Inhibition in Cancer
17:00—18:45
Engineered Immune Cell Strategies (5pm Start)
*
Philip D. Greenberg,
University of Washington, USA
Engineered T Cell Therapies for Solid Tumors
Engineered T Cell Therapies for Solid Tumors
*
Andrew M. Scharenberg,
Umoja Biopharma, USA
Novel T Cell Engineering Strategies
Novel T Cell Engineering Strategies
Katy Rezvani,
University of Texas MD Anderson Cancer Center, USA
CAR-NK Cells
CAR-NK Cells
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge additional support for this conference from:
|
Cancer Immunology Research |
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |
